Heron Therapeutics, Inc. (HRTX) key performance indicators and operating metrics (9 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Total Product Net Revenues | 34.71M | FY2026-Q1 |
| APONVIE Net Product Sales | 3.39M | FY2026-Q1 |
| CINVANTI Net Product Sales | 20.54M | FY2026-Q1 |
| ZYNRELEF Net Product Sales | 10.24M | FY2026-Q1 |
| Acute Care Franchise Net Product Sales | 13.63M | FY2026-Q1 |
| Cash Cash Equivalents and Short-Term Investments | 44.8M | FY2026-Q1 |
| Oncology Franchise Net Revenue | 24.24M | FY2025-Q4 |
| Sustol Net Product Sales | 1.31M | FY2025-Q4 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA) | 1.77M | FY2025-Q2 |
Back to HRTX overview · HRTX earnings · HRTX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.